[{"id":"99f4875a-0520-4340-a630-53ddf9fb3ea7","acronym":"PRISMM","url":"https://clinicaltrials.gov/study/NCT04447651","created_at":"2021-01-18T21:24:05.813Z","updated_at":"2025-02-25T14:29:23.488Z","phase":"","brief_title":"Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)","source_id_and_acronym":"NCT04447651 - PRISMM","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" SF3B1 • SRSF2 • U2AF1","pipe":" | ","alterations":" SF3B1 mutation • SRSF2 mutation • U2AF1 mutation","tags":["SF3B1 • SRSF2 • U2AF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation • SRSF2 mutation • U2AF1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/17/2020","start_date":" 09/17/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-08-02"},{"id":"711f8265-575f-4a14-bb60-be585609d334","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024994","created_at":"2021-08-27T12:53:02.872Z","updated_at":"2025-02-25T13:35:55.158Z","phase":"Phase 2","brief_title":"A Study of E7820 in People With Bone Marrow (Myeloid) Cancers","source_id_and_acronym":"NCT05024994","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation","tags":["FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7820"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-07-03"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"e36ce158-5d2c-43a5-8d9f-4bf96a854310","acronym":"ALLO-BAT","url":"https://clinicaltrials.gov/study/NCT04217356","created_at":"2021-01-18T20:31:57.752Z","updated_at":"2024-07-02T16:35:13.310Z","phase":"","brief_title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","source_id_and_acronym":"NCT04217356 - ALLO-BAT","lead_sponsor":"University Health Network, Toronto","biomarkers":" TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation","tags":["TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 02/05/2026","study_completion_date":" 02/05/2026","last_update_posted":"2024-03-22"},{"id":"e269da79-0604-48d1-b827-a87f71b24b1d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03894852","created_at":"2021-01-18T19:11:04.641Z","updated_at":"2024-07-02T16:36:44.920Z","phase":"","brief_title":"SRSF2 Gene Mutation in Patients With t-MDS/AML","source_id_and_acronym":"NCT03894852","lead_sponsor":"Zeinab Albadry Mohammed Zahran","biomarkers":" RUNX1 • SRSF2","pipe":" | ","alterations":" SRSF2 mutation","tags":["RUNX1 • SRSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SRSF2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 06/02/2019","start_date":" 06/02/2019","primary_txt":" Primary completion: 12/29/2019","primary_completion_date":" 12/29/2019","study_txt":" Completion: 04/29/2020","study_completion_date":" 04/29/2020","last_update_posted":"2020-05-19"}]